Keywords
Secondary prevention
Acute myocardial infarction
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To investigate the use of aspirin in the secondary prevention of acute myocardial infarction. Methods: This is an integrative review, with articles published between 2019 and 2024 in Portuguese, English and Spanish and with the content available in full. As a guiding question, the following was used: “Is the use of aspirin for secondary prevention of acute myocardial infarction recommended?” The bibliographic research was carried out in the MedLine, Latin American and Caribbean Literature in Health Science (LILACS), and Spanish Bibliographic Index in Health Sciences (IBECS) databases during the months of April and May 2024. the Health Sciences Descriptors (DeCS): “Aspirin”, “Infarction” and “Secondary Prevention” with the Boolean operator “AND”. Results: The 12 publications meeting the inclusion and exclusion criteria reveal that the use of aspirin is recommended for secondary prevention of acute myocardial infarction, together with P2Y12 inhibitors. Final considerations: The use of aspirin for secondary prevention of acute myocardial infarction is essential and when associated with a P2Y12 inhibitor, it can enhance this protective effect for patients undergoing ICP.
References
AHA, AMERICAN HEART ASSOCIATION. 2014. Disponivel em: https ://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000029. Acessado em: 15 de março de 2024.
COLLET JP, et al. Diretrizes da ESC 2020 para o manejo de síndromes coronarianas agudas em pacientes que se apresentam sem elevação persistente do segmento ST. 2021.
DALEN, J. E. et al. Should Senior Citizens Take Aspirin Daily to Prevent Heart Attacks or Strokes? Am J Med, 2021; 1185–1188.
DAVIDSON KW, et al. Uso de aspirina para prevenir doenças cardiovasculares: Declaração de recomendação da força-tarefa de serviços preventivos dos EUA. JAMA. 2022.
DE LUCA L, et al. How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study. Clin Cardiol, 2019; 1113–1120.
FUSTER V, JOSEPH M. Aspirina: uma visão terapêutica histórica e contemporânea. 2011.
GÉNÉREUX P, et al. Incidência, preditores e impacto do sangramento pós-alta após intervenção coronária percutânea. J Sou Coll Cardiol. 2015.
LEE K, et al. Impact of Age on Antiplatelet Monotherapy in the Chronic Maintenance Period After Percutaneous Coronary Intervention: A Post Hoc Analysis From the HOST-EXAM Extended Study. Can J Cardiol, 2024; 43–52.
LIU D, et al. Efficacy and safety of clopidogrel versus aspirin monotherapy for secondary prevention in patients with coronary artery disease: a meta-analysis. Front Cardiovasc Med, 2023; 1265983–1265983.
MAQSOOD M.H, et al. Do We Still Need Aspirin in Coronary Artery Disease? J Clin Med, 2023.
MARQUIS-GRAVEL G, et al. Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease. J Am Heart Assoc.p. 2024; 026921-026921.
MOZAFFARIAN S, et al. Short- and Long-term Myocardial Infarction Survival Rate According to the Type of Drugs Prescribed at the Time of Discharge: A Study Using Iran National Registry Data. Arch Iran Med, 2022; 105–111.
MURPHY E, et al. Aspirin in the Modern Era of Cardiovascular Disease Prevention. Methodist Debakey Cardiovasc J, 2021; 36–47.
MYLES, P. S. et al. Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial. J Thorac Cardiovasc Surg, 2019; 633–640.
NICOLAU JC, et al. Guidelines for Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction of the Brazilian Society of Cardiology, 2007.
QU J, et al. Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery. J Am Heart Assoc, 2021; 020413–020413.
RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2. The Lancet, 1988; 332(8607): 349–360.
SOCIEDADE BRASILEIRA DE CARDIOLOGIA,, 2015. Disponivel em: http ://publicacoes.cardiol.br/2014/diretrizes/2015/02_TRATAMENTO%20DO%20IAM%2
COM%20SUPRADESNIVEL%20DO%20SEGMENTO%20ST.pdf. Acessado em: 14 março de 2024.
SOCIEDADE CARDIOVASCULAR DE ANGIOGRAFIA E INTERVENÇÃO PARA REVASCULARIZAÇÃO DA ARTÉRIA CORONÁRIA, 2021. Acessado em: https ://pebmed.com.br/acc-2021-revascularizacao-completa-reduz-eventos-na-doenca-coronaria-cronica/. Acessado em: 14 março de 2024.
STOLAREK, W. et al. High on-treatment platelet reactivity to aspirin in patients after myocardial infarction. Biomed Pharmacother, 2022; 112618–112618.
THYGESEN T, et al. Terceira definição universal de enfarte do miocárdio. Rev Port Cardiol, 2013; 32(78): 643: 1-643.16.
WIEBE J, et al. Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta-Analysis. J Am Heart Assoc, 2021; 018304–018304.
YEH RW, et al. Desenvolvimento e validação de uma regra de predição de benefícios e danos da terapia antiplaquetária dupla além de 1 ano após intervenção coronária percutânea. J Am Med Assoc. 2016.